Tizanidine Tablet
Product Images NDC 63187-493

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 63187-493). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

63187-493-30 (Image 01)

Tizanidine 4 mg tablets label from Proficient Rx LP. The label states each tablet contains 4 mg tizanidine base equivalent to 4.576 mg tizanidine hydrochloride USP with 90 count. Tablets are white to off-white, round, flat, bevel edged, and debossed with "U" and "169" on opposite sides. Manufacturer is Unichem Laboratories Ltd, India. Includes storage instructions and a warning that Tizanidine tablets are not interchangeable with capsules.*

FDA Label Image

Tizanidine Hydrochloride (Tizanidinetabsusp Figure 01)

Chemical structure of tizanidine hydrochloride, showing a chlorinated benzene ring fused to a thiazole ring with an attached imidazoline moiety.*

FDA Label Image

Figure 1 (Tizanidinetabsusp Figure 02)

A line graph depicting plasma tizanidine concentration (ng/mL) over 24 hours post-dosing for 4 mg tizanidine tablets and capsules under fed and fasting conditions. The graph compares concentration profiles for tablets with and without food and capsules with and without food, showing peak levels and decline over time.*

FDA Label Image

Figure 2 (Tizanidinetabsusp Figure 03)

A line graph showing improvement in Ashworth Score over 6 hours post-dose for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The vertical axis represents improvement in Ashworth Score; the horizontal axis represents hours after dose. Both tizanidine doses show greater improvement than placebo, peaking at about 2 hours post-dose.*

FDA Label Image

Figure 3 (Tizanidinetabsusp Figure 04)

A chart showing improvement in Ashworth Score comparing tizanidine (mean dose 28.8 mg) and placebo at three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). The graph includes error bars for variability in scores.*

FDA Label Image

Company Logo (Tizanidinetabsusp Figure 05)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.